4.6 Article

Patients with a high proportion of immature and meiotically resistant oocytes experience defective nuclear oocyte maturation patterns and impaired pregnancy outcomes

Journal

REPRODUCTIVE BIOMEDICINE ONLINE
Volume 36, Issue 4, Pages 396-407

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.rbmo.2017.12.021

Keywords

Ca2+ signalling; Chromosome misalignment; Immature oocytes; Meiosis resistant; Nuclear maturation; Spindle abnormality

Funding

  1. FWO Vlaanderen (Flemish Fund for Scientific Research) [G060615N]
  2. China Scholarship Council [2010616105]
  3. Special Research Fund from Ghent University (Bijzonder Onderzoeksfonds, BOF) [01SC3712]
  4. University of Antwerp [TTBOF/29267]

Ask authors/readers for more resources

Patients presenting with abnormally high numbers of immature oocytes at retrieval are more likely to exhibit maturation resistant oocytes. However, the clinical relevance of such events remains unknown. We investigated nuclear maturation competence of immature oocytes from patients showing >40% of collected immature oocytes (Study group) and Controls, in which a normal number of mature oocytes (>= 60%) was retrieved. Following in-vitro culture, oocytes were classified as maturation resistant or in-vitro matured (IVM). Treatment outcomes were evaluated in Study and Control groups based on presence of maturation resistant oocytes. Overall, similarly high spindle and chromosome abnormality rates were observed in maturation resistant oocytes from both Study and Control groups. IVM oocytes from the Study group revealed significantly higher percentages of misaligned chromosomes compared with Controls (P < 0.05). Remarkably, Study group patients with at least one maturation resistant oocyte showed significantly reduced cumulative pregnancy and live birth rates compared with Control group maturation resistant patients (P < 0.05). When further investigating the aetiology, a maturation resistant mouse model revealed defective Ca2+ signalling of maturation resistant oocytes at germinal vesicular breakdown and parthenogenetic activation. In conclusion, appropriate treatment strategies, including clinical utilization of IVM oocytes from Study group patients, warrant further investigation. (c) 2018 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available